SCHEMBL4359292

SCHEMBL4359292

Oc1c(Cl)cccc1NCc1ccccc1Sc1ccc(Cl)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.40
HTR3A P46098 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
SLC6A4 P31645 3/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A3 Q01959 2/20 0.38
MAPT P10636 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ATM Q13315 1/20 0.37
ALOX12 P18054 3/20 0.36
MAPK1 P28482 2/20 0.36
CA1 P00915 1/20 0.36
ACHE P22303 1/20 0.36
POLB P06746 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4342478 0.90 HTR1A (0.39) HTR1AHTR3ASMN1; SMN2CA12CA2
SCHEMBL4343540 0.89 L3MBTL1 (0.46) HTR1AHTR3ASMN1; SMN2CA12CA2
SCHEMBL4357669 0.88 GAA (0.40) HTR1AHTR3ASMN1; SMN2CA12CA2
SCHEMBL4345495 0.88 SLC6A4 (0.52) SMN1; SMN2CA12CA2CA9SLC6A4
SCHEMBL4346907 0.87 SLC6A4 (0.48) SMN1; SMN2CA12CA2CA9SLC6A4
SCHEMBL4351156 0.87 SMN1; SMN2 (0.43) SMN1; SMN2CA12CA2CA9SLC6A4
SCHEMBL4341565 0.86 PTPRG (0.46) SMN1; SMN2MAPTMEN1KMT2AHPGD
SCHEMBL4351207 0.85 MEN1 (0.40) HTR1AHTR3ASMN1; SMN2CA12CA2
SCHEMBL4346759 0.85 SMN1; SMN2 (0.41) HTR1AHTR3ASMN1; SMN2CA12CA2
SCHEMBL4345359 0.85 SLC6A4 (0.40) SMN1; SMN2CA12CA2CA9SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 HTR1A 1211/4885HTR3A 1091/4885SMN1; SMN2 1791/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 HTR1A 1434/4885HTR3A 1178/4885SMN1; SMN2 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.